GH ▼ -1.0% - Guardant Health, Inc.
$GH Guardant Health Announces Approval in Europe of Guardant360® CDx as Companion Diagnostic for AstraZeneca’s ETCAMAH™ (camizestrant) in Advanced ER-positive Breast Cancer
08-OCT-2026 04:14 PM ET
Share this post
More filings for $GH
GH - Guardant Health, Inc. - SEC Filing Update (14-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 14, 2026$GH SEC Filing Update (28-JUL-2026) | ThinkSabio - Stocks SimplifiedJul 28, 2026
View full $GH filing history →💬 Comments
Loading comments…
Leave a comment